- •DeepSeek V4 Flash argues HOLD because The original short thesis remains intact: ABBV has declined 7 consecutive sessions on guidance concerns, with price now at $245.61, 64.3% of the way to the $240 target. The 4h trend structure is bearish (price below SMA20, RSI falling, MACD negative), sector confirmation from XLV supports the move, and the $240 target is still reachable with clear air below. The remaining 7 days of the 15-day horizon provide sufficient time for the guidance-driven repricing to reach the target, especially with US CPI as a potential catalyst that could accelerate risk-off flows.
- •What changed: ABBV has extended its losing streak to 7 consecutive sessions since entry, with price declining from $255.18 to $245.61 (-3.8%). Volume has dropped to the 2nd percentile (depressed). BMO Capital raised its price target to $300. US CPI is within 3 days as a high-impact macro event. The position has reached 64.3% progress toward the $240 target.
The original short thesis remains intact: ABBV has declined 7 consecutive sessions on guidance concerns, with price now at $245.61, 64.3% of the way to the $240 target. The 4h trend structure is bearish (price below SMA20, RSI falling, MACD negative), sector confirmation from XLV supports the move, and the $240 target is still reachable with clear air below. The remaining 7 days of the 15-day horizon provide sufficient time for the guidance-driven repricing to reach the target, especially with US CPI as a potential catalyst that could accelerate risk-off flows.
The original short thesis for ABBV remains intact. The guidance-driven sell-off has extended to seven sessions, and the stock is exhibiting bearish momentum with RSI and MACD confirming the downward trend. The price is approaching the $240.00 target, and the stop at $262.00 has not been compromised. The Healthcare sector's weakness supports the thesis, while the broader market's bullish regime has not overridden ABBV's company-specific challenges.
The short is +3.8% in-the-money at $245.42 with the original guidance-concern catalyst intact through a seventh straight down session, 4h momentum still bearish (RSI 47.93 falling, MACD histogram negative below SMA20 $251.55), and XLV confirming sector weakness. Target $240 is only ~2.2% away with the effective stop at $251.77 preserving asymmetric R/R, so the transmission path from thesis to target remains open.
No model argued for EXIT.
- →CPI prints soft, triggering a risk-on rotation that lifts ABBV off support before the $240 target is reached; BMO's $300 target upgrade gains traction as dip-buyers emerge, and the depressed volume (2nd percentile) means the move lacks conviction selling, making a snap-back possible on any positive catalyst.
Individual Model Review
The short is +3.8% in-the-money at $245.42 with the original guidance-concern catalyst intact through a seventh straight down session, 4h momentum still bearish (RSI 47.93 falling, MACD histogram negative below SMA20 $251.55), and XLV confirming sector weakness. Target $240 is only ~2.2% away with the effective stop at $251.77 preserving asymmetric R/R, so the transmission path from thesis to target remains open.
The short is +3.8% in-the-money at $245.42 with the original guidance-concern catalyst intact through a seventh straight down session, 4h momentum still bearish (RSI 47.93 falling, MACD histogram negative below SMA20 $251.55), and XLV confirming sector weakness. Target $240 is only ~2.2% away with the effective stop at $251.77 preserving asymmetric R/R, so the transmission path from thesis to target remains open.
▼ Click to expandThe move is 64.3% complete off a 77.8% peak, showing some give-back, and short-term 30m signals (rising RSI, positive MACD histogram at support $245.19) hint at a bounce. The July 15 ex-dividend catalyst, a BMO PT raise to $300, a soft-bullish equity regime, and CPI in 3 days could fuel a relief rally that reclaims $247.56 and threatens the position.
▼ Click to expandThe original short thesis remains intact: ABBV has declined 7 consecutive sessions on guidance concerns, with price now at $245.61, 64.3% of the way to the $240 target. The 4h trend structure is bearish (price below SMA20, RSI falling, MACD negative), sector confirmation from XLV supports the move, and the $240 target is still reachable with clear air below. The remaining 7 days of the 15-day horizon provide sufficient time for the guidance-driven repricing to reach the target, especially with US CPI as a potential catalyst that could accelerate risk-off flows.
The original short thesis remains intact: ABBV has declined 7 consecutive sessions on guidance concerns, with price now at $245.61, 64.3% of the way to the $240 target. The 4h trend structure is bearish (price below SMA20, RSI falling, MACD negative), sector confirmation from XLV supports the move, and the $240 target is still reachable with clear air below. The remaining 7 days of the 15-day horizon provide sufficient time for the guidance-driven repricing to reach the target, especially with US CPI as a potential catalyst that could accelerate risk-off flows.
▼ Click to expandThe position should be closed because the move has been driven by depressed volume (2nd percentile), suggesting lack of conviction selling rather than structural repricing. BMO Capital raised its price target to $300, signaling analyst confidence in the immunology franchise. The 7-day losing streak may be extended and due for a mean-reversion bounce, especially with CPI risk that could trigger a relief rally. The risk/reward has deteriorated from entry with only $5.61 remaining to target versus potential for a snap-back to the 4h SMA20 at $251.55.
▼ Click to expandThe original short thesis for ABBV remains intact. The guidance-driven sell-off has extended to seven sessions, and the stock is exhibiting bearish momentum with RSI and MACD confirming the downward trend. The price is approaching the $240.00 target, and the stop at $262.00 has not been compromised. The Healthcare sector's weakness supports the thesis, while the broader market's bullish regime has not overridden ABBV's company-specific challenges.
The original short thesis for ABBV remains intact. The guidance-driven sell-off has extended to seven sessions, and the stock is exhibiting bearish momentum with RSI and MACD confirming the downward trend. The price is approaching the $240.00 target, and the stop at $262.00 has not been compromised. The Healthcare sector's weakness supports the thesis, while the broader market's bullish regime has not overridden ABBV's company-specific challenges.
▼ Click to expandExiting the position now would be premature as the original thesis has not been invalidated. The stop remains intact, and the target is within reach. While the broader market regime is bullish, ABBV's weakness is company-specific and not yet reversed. Exiting early would risk missing the remaining downside potential and violate the strategy's focus on maximizing P&L through asymmetric risk/reward setups.
▼ Click to expandRun Summary
Intraday discovery triggered reanalysis on ABBV. Verdict: HOLD (0/3 EXIT). Conviction: 95.